Juan Marquet

TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

TL;DR: The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain and patients with cancer and Covid- 19 have been described to have a higher risk of suffering severe events.

TL;DR: In this paper, the authors investigated the impact of CLL-directed treatments on the course of Coronavirus disease 2019 (COVID-19) and found that patients with chronic lymphocytic leukemia (CLL) may be more susceptible to the disease due to age, disease, and treatment-related immunosuppression.

TL;DR: In a “real‐world” setting, frontline treatment with O‐Clb achieves PFS comparable to that reported in clinical trials and can be still considered as legitimate frontline therapy for unfit CLL patients with low‐risk disease.

TL;DR: In this article, the authors analyzed the infectious complications in patients with lymphoproliferative diseases (LPD) treated with targeted therapies in real-life setting, in 18 Spanish institutions, from the time of their commercial availability to August 2020.